Analysts tend to be always conservative - however in the valuation, I notice they say,
"We arrive at this valuation by projecting future revenue from CHECKvacc in TNBC, HER-Vaxx in advanced HER2+ gastric cancer, and PD1-Vaxx in NSCLC. Commercial success outside these financially modeled programs would serve as potential upside to our valuation"
I know this doesn't include oncarlytics, however this is three shots that are successful. This seems a lot less (72c) than the numbers that some seem to throw up (On multi bagger thread) assuming Imu is successful - $2-$3 and so on.
- Forums
- ASX - By Stock
- IMU
- Analysts Reports (Imugene)
Analysts Reports (Imugene), page-168
-
-
- There are more pages in this discussion • 171 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMU (ASX) to my watchlist
|
|||||
Last
5.5¢ |
Change
0.003(5.77%) |
Mkt cap ! $404.2M |
Open | High | Low | Value | Volume |
5.2¢ | 5.7¢ | 5.2¢ | $802.5K | 14.79M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 348447 | 5.4¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
5.5¢ | 1214875 | 6 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 348447 | 0.054 |
9 | 425998 | 0.053 |
13 | 2137592 | 0.052 |
21 | 4150130 | 0.051 |
39 | 3576889 | 0.050 |
Price($) | Vol. | No. |
---|---|---|
0.055 | 700000 | 4 |
0.056 | 556147 | 3 |
0.057 | 1055166 | 8 |
0.058 | 410000 | 6 |
0.059 | 292981 | 9 |
Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
Featured News
IMU (ASX) Chart |